First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment: the RAAFT-3 Trial

Age
99 years or below
Gender
All
participants needed
10
Location
1

Brief description of study

To determine if catheter-based atrial fibrillation (AF) ablation is superior to treatment with antiarrhythmic drugs as a first-line therapy for symptomatic persistent AF

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Atrial Fibrillation, afib
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 829475
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research